Cofoe Medical Technology Co.Ltd.

Cofoe Medical released its 2026 interim report. During the reporting period, the company achieved total operating revenue of 2.072 billion yuan and net profit attributable to the parent company of 202 million yuan. Net cash inflow from operating activities was 262 million yuan, a decrease of 89.0221 million yuan compared with the same period last year, down 25.33 percent year on year. The company's latest asset-liability ratio was 25.41 percent, an increase of 0.62 percentage points from the same period last year. Gross margin was 55.89 percent, return on equity was 3.66 percent, and diluted earnings per share was 0.95 yuan. The number of shareholders was 15,200, and the top ten shareholders held a combined 159 million shares, accounting for 67.46 percent of the total share capital.

Cofoe Medical released its 2026 half-year report. In the first half, revenue reached 2.072 billion yuan, up 38.51% year on year. Net profit attributable to the parent company was 202 million yuan, up 20.84%, and non-GAAP net profit was 173 million yuan, up 26.73%. Core categories accelerated their volume growth, with revenue from the top five single products rising 50% year on year. Ventilators performed particularly well, with second-quarter sales exceeding 100 million yuan. In the first half, respiratory support revenue was 267 million yuan, up 166.90% year on year. The company launched a new-generation AI ventilator, the C11, helping move the product into home sleep health management scenarios. Other categories also maintained growth. Revenue from traditional Chinese medicine therapy and other businesses rose 114.54% year on year, while rehabilitation aids, medical care, and health monitoring grew 31.74%, 20.68%, and 11.70% respectively. The company continued to introduce new products, established an artificial intelligence research institute, and cooperated with partners including Royal Philips, Huawei Device, and Tencent Cloud. Seventeen products have now been connected to the HarmonyOS ecosystem. Overseas revenue in the first half was 210 million yuan, up 117% year on year. The company listed on the main board of the Hong Kong Stock Exchange on May 6, forming a dual capital platform across A-shares and H-shares.

Cofoe Medical announced on August 28 that it plans to distribute a cash dividend of 6 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 136 million yuan. In the first half of 2026, the company achieved revenue of 2.072 billion yuan and net profit attributable to the parent of 202 million yuan.

Cofoe Medical and Philips launched a strategic cooperation project at the 19th Xipu Conference, titled "Philips home health measurement devices empower the upgrade of China's health stations," to accelerate the rollout of pharmacy health services. Since reaching a strategic partnership in December 2025, the two sides have integrated Philips' cutting-edge health smart technologies with Cofoe Medical's localized R&D, manufacturing, and channel operation capabilities to drive AI technology into home health scenarios. The Philips smart health solution released this time uses home health measurement devices as the entry point, a dedicated home health management app as the digital foundation, and an AI health assistant as the core enabler, helping residents build electronic health records covering key indicators such as blood pressure, blood glucose, blood oxygen, body temperature, and body composition. It also provides pharmacies with practical tools for health testing, chronic disease management, health consultation, and refined member operations. Cofoe Medical Vice President Yu Xiangyu said that health stations aim to help pharmacies transform from one-time transaction venues into sustainably operated community health service nodes.

Cofoe Medical announced that on July 22, the company completed its first buyback of 496,200 A-shares through a dedicated repurchase securities account via centralized bidding, representing 0.24% of total share capital. The highest transaction price was RMB 53.87 per share, the lowest was RMB 50.60 per share, and the total transaction amount was RMB 26.1054 million. The company previously held a board meeting on June 26, 2026, and an extraordinary general meeting on July 20, approving a share buyback plan. It intends to use its own funds and a special stock buyback loan to repurchase some A-shares via centralized bidding, with a buyback amount of no less than RMB 100 million and no more than RMB 200 million, and a maximum buyback price of RMB 69.66 per share. Based on this calculation, the number of shares to be repurchased ranges from 1.4355 million to 2.8711 million, accounting for 0.61% to 1.22% of total share capital. The buyback period is within 12 months from the date of approval by the general meeting, and all repurchased shares will be cancelled to reduce registered capital.